Medistrategies International Promoting Viraguard® Hospital Wipes With New EPA - Approved Label Claims For Hepatitis A, B and C To Medical Group Purchasing Organizations - 3 Contracts Signed

Business Wire, Oct 31, 2005

ST. PETERSBURG, Fla. -- Veridien Corporation (OTCBB:VRDE) announced that its hospital contract development partner, Medistrategies International, is promoting the Viraguard(R) Hospital Wipes with their new EPA-approved label claims for killing all three of Hepatitis A, B and C, to Medical Group Purchasing Organizations (GPO's).

According to the U.S. Centers for Disease Control, 4.95 million Americans are afflicted with Hepatitis A, B and C. Over 160,000 people contract Hepatitis annually(1). The patented Viraguard(R) formula is the only EPA approved disinfectant with Hepatitis A, B and C label claims that is also drug listed by the FDA as a hand antiseptic product.

Medistrategies International was retained by Veridien to develop extensive hospital buying contracts for Viraguard(R) Infection Control Products. Since July 2005, Veridien has obtained three major hospital chain contracts (MHA, MAGNET and PDM Healthcare) that represent access to more than 1.4 million long term care beds, over 775 hospitals, 1,300 alternate care facilities and 12,000 healthcare providers. Veridien and Medistrategies are in active discussions with two other GPO's that negotiate for over $12.8 billion dollars of healthcare products annually across the United States.

Dennis Daar, managing partner of Medistrategies International said, "This breakthrough label approval of Hepatitis A, B and C kill claims on surface disinfecting wipes confirms our confidence that the patented Viraguard(R) disinfectant and antiseptic formula is the premiere infection control solution in the medical marketplace. Viraguard(R) Antiseptic Hand Wipes and Hospital Surface Disinfectant Towelettes are unique given the Hepatitis A, B and C kill claims. This competitive edge for Viraguard(R) is undeniable."

Viraguard(R) Infection Control products are available to healthcare practitioners and industrial materials managers through major distributors across the United States. Viraguard(R) Products can also be purchased for use at home or at the office at www.buyveridien.com.

(1) (www.cdc.gov/ncidod/diseases/hepatitis/resource/dz_burden02.htm)

About Veridien:

For more information about Veridien Corporation and it investments in future technology, please visit: www.veridien.com and www.mycosol.com.

Special Note: Forward-looking statements in this press release (identifiable by such words as "believes", "expects") are made pursuant to the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, market acceptance of, and demand for, the Company's products, manufacturing, development and distributor issues, product pricing, competition, funding availability, technological changes and other risks not identified herein. The Company disclaims any intent or obligation to update any forward-looking statements.